Overview

Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborator:
GlaxoSmithKline
Treatments:
Topotecan